Human Reproductive Technologies Market (Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 – 2019

Albany, NY -- (SBWire) -- 06/23/2015 --Human reproductive technologies comprise operations and therapies used to conceive or control pregnancy employing semi-artificial and/or artificial medical solutions. Reproductive technologies are employed for both male and female infertility problems. In the last few years there has been a tremendous increase in the prevalence of infertility all over the world. Lifestyle changes in the urban population leading to delays in the first pregnancy, use of contraceptive pills, and excess consumption of alcohol and tobacco are some of the factors leading to increased infertility rates globally and raising demand for human reproductive technologies.The global human reproductive technologies market stood at US$23.0 billion in 2012, and, growing at a CAGR of 2.2% between 2013 and 2019, the market is expected to be valued at US$27.1 billion in 2019.

Browse Full Global Human Reproductive Technologies Market Report With Complete TOC @ http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html

Rising Awareness about Available Technologies to Propel Market

As per the World Health Organization (WHO), in 2010, almost 1.9% of women in the age group 20-44 years were unable to conceive their first child, and 10.5% who had conceived once could not have subsequent pregnancies. Thus, high rate of infertility will offer opportunities to the global human reproductive technologies market.Increasing rate of both male and female infertility, rising awareness about available technologies for the treatment of reproductive problems, increasing incidence of unwanted pregnancies, and overall advancement in contraception technologies is boosting growth of the market. The global human reproductive technologies market is divided on two criteria, namely contraceptive technologies and infertility treatments. Based on contraceptive technologies, the market is sub-segmented into contraceptive drugs and devices. The contraceptive devices segment comprises male contraceptive devices (condoms) and female contraceptive devices, whereas the contraceptive drugs segment consists of topical contraceptives, oral contraceptive pills, and contraceptive injectable.

Browse the full Press Release:
http://www.transparencymarketresearch.com/pressrelease/human-reproductive-technologies-market.htm

Ease of Use to Help Oral Contraceptive Pills Dominate Contraceptive Drugs Segment

In 2012, the overall contraceptives market was valued at US$16.0 billion, and is expected to grow at a CAGR of 5.5% between 2013 and 2019. In the contraceptive drugs segment of the market, oral contraceptive pills accounted for the highest revenue in 2012. Easy availability of over-the-counter pills and increasing awareness about oral contraceptive pills is the major growth driver of the market.In the same year, male condoms dominated the contraceptive devices segment owing to ease of use, higher availability, and lack of side effects with the device. Increased conception rate and higher incidence of unwanted pregnancies and sexually transmitted diseases (STDs) will propel the overall contraceptive technologies market.

U.S. FDA Accreditation to Help Viagra Lead Infertility Drugs Segment

The infertility technologies segment of the human reproductive technologies market is divided on the basis of drugs and treatment procedures. By infertility drugs, the human reproductive technologies market involves three major classes, which are gonadotropins, erectile dysfunction drugs, and androgens.

Some of the leading drug brands in these classes include Gonal-f, AndroGel, Viagra, Levitra/Staxyn, Follistim AQ Testim, and Cialis. Viagra emerged as the largest drug brand by revenue in 2012 and has been approved by the U.S. FDA since 1998. Owing to rising incidence of erectile dysfunction, Viagra continues to lead the global infertility drugs market.AndroGel accounts as the most preferred drug for testosterone deficiency, and Gonal-f, which is a gonadotropin, is widely prescribed for infertility issues.

Request a Brochure of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1876

About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact:
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com